Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …

Lung cancer is the leading cause of cancer mortality. It is classified into different histologic
subtypes, including adenocarcinoma, squamous carcinoma, and large cell carcinoma …

HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers.
We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug …

Non-small-cell lung cancer (NSCLC) harbouring HER2 alterations is now considered a
distinct molecular subtype. The activation of HER2 in NSCLC occurs via three mechanisms …

PURPOSE Insertion mutations in Erb-b2 receptor tyrosine kinase 2 gene (ERBB2 or HER2)
exon 20 occur in 2%-5% of non–small-cell lung cancers (NSCLCs) and function as an …

PURPOSE Targeted therapies against non–small-cell lung cancer (NSCLC) harboring
HER2 mutations remain an unmet need. In this study, we assessed the efficacy and safety of …

Human epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth
factor receptor family having tyrosine kinase activity. Dimerization of the receptor results in …

The introduction of HER2-targeted therapy for breast and gastric patients with ERBB2
(HER2) amplification/overexpression has led to dramatic improvements in oncologic …

First-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provide significant clinical
benefit in patients with advanced EGFR-mutant (EGFRm+) non–small cell lung cancer …

Targeted therapies are substantially changing the management of lung cancers. These
treatments include drugs that target driver mutations, those that target presumed important …